{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:08:39Z","timestamp":1788905319690,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100267","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:29:39Z","timestamp":1783117779000},"page":"100267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8972-7883","authenticated-orcid":false,"given":"Caitlin","family":"Unkenholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ortega-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Gordillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Esteban","family":"Velez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-5449","authenticated-orcid":false,"given":"Mark","family":"Bustoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-5597","authenticated-orcid":false,"given":"Mateo","family":"Mejia Saldarriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bneo.2026.100267_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cpt.2022.11.002","article-title":"Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myeloma","volume":"1","author":"Lu","year":"2023","journal-title":"Cancer Pathog Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100267_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100267_bib6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3109\/10428194.2013.873537","article-title":"Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival","volume":"55","author":"Jimenez-Zepeda","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.bneo.2026.100267_bib7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.V110.11.2737.2737","article-title":"Atypical serum immunofixation pattern (ASIP) development during induction therapy with BiRD for newly diagnosed multiple myeloma correlates with a high rate of complete remission","volume":"110","author":"Mark","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100267_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2008.07374.x","article-title":"Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma","volume":"143","author":"Mark","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100267_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bjhh.2017.05.010","article-title":"For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission","volume":"39","author":"Silva","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"11","key":"10.1016\/j.bneo.2026.100267_bib10","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/cas.12527","article-title":"Oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival","volume":"105","author":"Fujisawa","year":"2014","journal-title":"Cancer Sci"},{"issue":"10297","key":"10.1016\/j.bneo.2026.100267_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bneo.2026.100267_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100267_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bneo.2026.100267_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.bneo.2026.100267_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100267_bib16","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1182\/blood.V84.12.4374.bloodjournal84124374","article-title":"Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation","volume":"84","author":"Gerritsen","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100267_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1365-2141.1999.01233.x","article-title":"Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation","volume":"104","author":"Guikema","year":"1999","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.bneo.2026.100267_bib18","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Mejia Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2026.100267_bib19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cimb47080640","article-title":"Serum immunoglobulin changes in multiple myeloma patients treated with CAR T-cell therapy","volume":"47","author":"Burger","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100267_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70054","article-title":"The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCAM-CAR-T cell therapy: a retrospective study based on LEGEND-2","volume":"8","author":"Liu","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.bneo.2026.100267_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/bloodadvances.2021005814","article-title":"Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"6","author":"Liang","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"10.1016\/j.bneo.2026.100267_bib1","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S2152-2650(24)01957-8","article-title":"Abnormal serum fixation patterns are a common event following BCMA CAR-T in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]","volume":"24","author":"Saldarriaga","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100267_bib2","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood-2024-210365","article-title":"Abnormal serum fixation patterns are a common event following BCMA CAR-T therapy in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]","volume":"144","author":"Unkenholz","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100267_bib3","series-title":"Abnormal serum fixation patterns (ASIP) are a common event following BCMA CAR-T in relapsed refractory multiple myeloma and are often preceded by immunological events","author":"Unkenholz","year":"2025"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:28:59Z","timestamp":1788902939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000786"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100267","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100267"}}